MD520Z - Metodă de tratament postoperator al pacienţilor cu litiază renală - Google Patents
Metodă de tratament postoperator al pacienţilor cu litiază renală Download PDFInfo
- Publication number
- MD520Z MD520Z MDS20110192A MDS20110192A MD520Z MD 520 Z MD520 Z MD 520Z MD S20110192 A MDS20110192 A MD S20110192A MD S20110192 A MDS20110192 A MD S20110192A MD 520 Z MD520 Z MD 520Z
- Authority
- MD
- Moldova
- Prior art keywords
- day
- days
- biomass
- extract
- cnm
- Prior art date
Links
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims abstract description 11
- 206010029148 Nephrolithiasis Diseases 0.000 title abstract description 5
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 19
- 239000002028 Biomass Substances 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 19
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 18
- 230000001858 anti-Xa Effects 0.000 claims abstract description 10
- 229960005153 enoxaparin sodium Drugs 0.000 claims abstract description 9
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 4
- 238000001784 detoxification Methods 0.000 claims abstract description 4
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 3
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 241000192700 Cyanobacteria Species 0.000 claims description 6
- 206010038478 Renal lithiasis Diseases 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 238000009160 phytotherapy Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 6
- 241001464430 Cyanobacterium Species 0.000 abstract description 4
- 208000000913 Kidney Calculi Diseases 0.000 abstract description 4
- 229940124575 antispasmodic agent Drugs 0.000 abstract 1
- -1 antispasmodics Substances 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000012273 nephrostomy Methods 0.000 description 5
- 238000007487 urography Methods 0.000 description 5
- 206010007027 Calculus urinary Diseases 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000008281 urolithiasis Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 206010037596 Pyelonephritis Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229960004755 ceftriaxone Drugs 0.000 description 3
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 230000002784 sclerotic effect Effects 0.000 description 3
- 239000008279 sol Substances 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229960004752 ketorolac Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000000381 Familial Hypophosphatemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000010143 cystone Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- OMFNSKIUKYOYRG-MOSHPQCFSA-N drotaverine Chemical compound C1=C(OCC)C(OCC)=CC=C1\C=C/1C2=CC(OCC)=C(OCC)C=C2CCN\1 OMFNSKIUKYOYRG-MOSHPQCFSA-N 0.000 description 1
- 229960002065 drotaverine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000010245 tubular reabsorption Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110192A MD520Z (ro) | 2011-12-06 | 2011-12-06 | Metodă de tratament postoperator al pacienţilor cu litiază renală |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20110192A MD520Z (ro) | 2011-12-06 | 2011-12-06 | Metodă de tratament postoperator al pacienţilor cu litiază renală |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD520Y MD520Y (en) | 2012-06-30 |
| MD520Z true MD520Z (ro) | 2013-01-31 |
Family
ID=46512861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20110192A MD520Z (ro) | 2011-12-06 | 2011-12-06 | Metodă de tratament postoperator al pacienţilor cu litiază renală |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD520Z (mo) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435184A (zh) * | 2013-09-25 | 2015-03-25 | 廖国建 | 一种治疗肾结石的药物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1324669A1 (ru) * | 1985-12-30 | 1987-07-23 | Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств | Средство дл лечени уролитиаза |
| SU1572625A1 (ru) * | 1987-12-28 | 1990-06-23 | Центральная Медико-Санитарная Часть N15 | Способ лечени уролитиаза |
-
2011
- 2011-12-06 MD MDS20110192A patent/MD520Z/ro not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1324669A1 (ru) * | 1985-12-30 | 1987-07-23 | Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств | Средство дл лечени уролитиаза |
| SU1572625A1 (ru) * | 1987-12-28 | 1990-06-23 | Центральная Медико-Санитарная Часть N15 | Способ лечени уролитиаза |
Non-Patent Citations (1)
| Title |
|---|
| Protocolul naţional. Urolitiaza la adulţi. Chişinău, 2009, p-14-40, găsit în internet, < URL: http://www.ms.gov.md/_files/6157-PCN-88%2520UA.pdf>. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435184A (zh) * | 2013-09-25 | 2015-03-25 | 廖国建 | 一种治疗肾结石的药物 |
Also Published As
| Publication number | Publication date |
|---|---|
| MD520Y (en) | 2012-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2011111770A1 (ja) | 慢性前立腺炎、間質性膀胱炎及び／又は排尿障害の改善又は治療剤 | |
| DK2422793T3 (en) | Pharmaceutical compositions for dehydration, eutrophication and removal of the pathological tissues | |
| MD520Z (ro) | Metodă de tratament postoperator al pacienţilor cu litiază renală | |
| RU2543344C2 (ru) | Способ лечения трофических язв | |
| Bailey et al. | Comparison of intermittent haemodialysis, prolonged intermittent renal replacement therapy and continuous renal replacement haemofiltration for lithium toxicity: a case report | |
| El-Agamy et al. | Protective role of panax gensing on fluvoxamine maleate induced structural changes in the submandibular salivary gland of rats | |
| Lemann Jr et al. | Kidney hematoma due to extracorporeal shock wave lithotripsy causing transient renin mediated hypertension | |
| CA2890120C (en) | Therapy for constipation | |
| CN102579528A (zh) | 一种防治前列腺疾病的药物组合物 | |
| CN100471508C (zh) | 一种治疗心脑血管疾病的药物及其制作方法 | |
| WO2019239963A1 (en) | Pharmaceutical composition for treating chronic constipation | |
| RU2419427C1 (ru) | Способ профилактики и комплексного лечения уролитиаза после дистанционной литотрипсии | |
| CN105147877A (zh) | 一种用于治疗甲沟炎的药物 | |
| CN101310757B (zh) | 一种治疗体癣及手足癣的药膏 | |
| CN112220860A (zh) | 一种尿毒症患者动静脉内瘘中药保护贴 | |
| Saunders | Nigella sativa dissolves small renal liths | |
| RU2185216C2 (ru) | Способ профилактики послеоперационных иммунодефицитов | |
| CN103893286A (zh) | 一种治疗慢性肾脏疾病的中药制剂及其制备方法 | |
| CN101181551B (zh) | 治疗痔疮的外用软膏 | |
| RU2250766C2 (ru) | Способ лечения туберкулеза предстательной железы | |
| CN108403740A (zh) | 八宝丹及其制剂在制备治疗血精症的药物中的应用 | |
| RU2164797C1 (ru) | Способ лечения воспалительных заболеваний околоносовых пазух | |
| CN106983799A (zh) | 一种治疗中心静脉留置导管管口周围的肉芽组织增生的药物组合物 | |
| RU2153334C2 (ru) | Способ лечения онкологического заболевания | |
| CN119792403A (zh) | 一种预防放射性口腔黏膜的壮药组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |